Cytokines are therapeutic targets for the treatment of patients with RA [tumor necrosis factor (TNF)] and in RA clinical trials [e.g., interleukin (IL)-1, IL-6, IL-27] (McInnes et al., 2016). This evidence concerns the gene IL6 and rheumatoid arthritis.